US StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

Cardiovascular

20.00

0.0000

Volume:- -

Turnover:- -

Market Cap:843.96M

PE:-20.84

High:20.00

Open:20.00

Low:20.00

Close:20.00

Loading ...

Overview Company News Filings

AngioDynamics to Host Virtual Cardiovascular Investor Event

Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM

Hengrui Medicine Grants Merck Sharp & Dohme Rights to Market Cardiovascular Drug; Shares Up 4%

MT Newswires Live

Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.

BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions

Merck (NYSE:MRK) Unveils New Data On Cardiovascular Advances At ACC.25 Annual Conference

Simply Wall St.

Press Release: AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event

Ansys and NVIDIA to Demonstrate New Era of In-Silico Cardiovascular Research at GTC

Press Release: Robotic Telesurgery Data from Collaboration with Corewell Health(TM) Accepted for Presentation at the Cardiovascular Research Technologies Annual Meeting

Globalspace Technologies Signs MoU for Maharashtra, India's Cardiovascular Disease Screening Project

MT Newswires Live

Medtronic Q3 Earnings: Cardiovascular And Neuroscience Drive Growth, Surgical Revenue Dips, Reaffirms Annual Forecast

Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)

Medtronic 3Q Revenue Rises on Strength in Cardiovascular, Neuroscience

Pharma Foods, National Cerebral and Cardiovascular Center Launch Cadasil Drug Research Department

MT Newswires Live

Positive Outlook on Esperion’s Bempedoic Acid (BDA) for High-Risk Cardiovascular Patients Driven by Promising CLEAR Outcomes Trial Results

Cardio Diagnostics Expands the Reach of its AI-Driven Precision Cardiovascular Medicine Tests by Partnering with Seven New Provider Organizations

Promising Potential of Esperion’s Non-Statin Drugs in Cardiovascular Disease Management

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/CSII/news?page=2"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"CSII","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSII\",,,,,undefined,":{"symbol":"CSII","market":"US","secType":"STK","nameCN":"Cardiovascular","latestPrice":20,"timestamp":1688155200000,"preClose":20,"halted":0,"volume":0,"delay":0,"floatShares":40687277,"shares":42198048,"eps":-0.959831,"marketStatus":"Pre-Mkt","change":0,"latestTime":"07-22 06:56:22 EDT","open":20,"high":20,"low":20,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-0.959831,"tradingStatus":1,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1753191000000},"marketStatusCode":1,"adr":0,"adrRate":0,"listingDate":1151467200000,"exchange":"NASDAQ","adjPreClose":20,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"CSII\",,,,,undefined,":{"symbol":"CSII","floatShares":40687277,"roa":"-7.56%","roe":"-15.18%","lyrEps":-0.941454,"shares":42198048,"dividePrice":0,"high":20,"amplitude":0,"preClose":20,"low":20,"week52Low":12.255,"pbRate":"3.53","psRate":"3.52","week52High":23.47,"institutionHeld":0.4085,"latestPrice":20,"eps":-0.959831,"divideRate":0,"volume":0,"delay":0,"ttmEps":-0.959831,"open":20,"prevYearClose":13.62},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"CSII\",pageSize:20,pageCount:2,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2524494166","title":"AngioDynamics to Host Virtual Cardiovascular Investor Event","url":"https://stock-news.laohu8.com/highlight/detail?id=2524494166","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2524494166?lang=en_us&edition=fundamental","pubTime":"2025-04-02 21:57","pubTimestamp":1743602249,"startTime":"0","endTime":"0","summary":"An update from AngioDynamics ( ($ANGO) ) is now available. On April 2, 2025, AngioDynamics will host a virtual Cardiovascular Investor Event, highl...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/angiodynamics-to-host-virtual-cardiovascular-investor-event?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/angiodynamics-to-host-virtual-cardiovascular-investor-event?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4181","CSII","BK4588","BK4585","ANGO","BK4218","HST","BK4082"],"gpt_icon":0},{"id":"2523940135","title":"Acoramidis Shows Statistically Significant Improvements in Cardiovascular Outcomes in Patients with Variant ATTR-CM","url":"https://stock-news.laohu8.com/highlight/detail?id=2523940135","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523940135?lang=en_us&edition=fundamental","pubTime":"2025-03-31 22:00","pubTimestamp":1743429600,"startTime":"0","endTime":"0","summary":"Acoramidis’s hazard ratio of .41 for time to ACM or first CVH versus placebo in the ATTRibute-CM study subgroup of ATTRv-CM patients achieved statistical significance in a pre-specified analysis. This profound treatment effect, due to the near-complete stabilization  and binding of TTR, represents the greatest observed benefit to date for ATTRv-CM patients, an ATTR-CM population with poor prognosis. In the ATTRibute-CM study, acoramidis demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date in both ATTRv-CM and ATTRw-CM patients:. In as few as 3 months, the time to first event  durably separated relative to placebo. A 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month 30. A 50% reduction in the cumulative frequency of CVH events relative to placebo at Month 30. Acoramidis is approved as Attruby by the U.S. FDA and is approved as BEYONTTRA by the European Commission and Japanese Pharmaceuticals and Medical Devices Agency","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/acoramidis-shows-statistically-significant-improvements-140000779.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CM","BK4139","BK4588","ACM","BK4516","CSII","BBIO","BK4505","BK4585","BK4082","BK4129","BK4207","LU2308191902.HKD"],"gpt_icon":0},{"id":"2522893642","title":"Hengrui Medicine Grants Merck Sharp & Dohme Rights to Market Cardiovascular Drug; Shares Up 4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2522893642","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522893642?lang=en_us&edition=fundamental","pubTime":"2025-03-26 12:39","pubTimestamp":1742963969,"startTime":"0","endTime":"0","summary":"Jiangsu Hengrui Medicine  granted US-based pharmaceutical giant Merck Sharp & Dohme the license for the HRS-5346 drug for $200 million, according to a Shanghai Stock Exchange filing on Tuesday.Merck Sharp & Dohme will be given the rights to develop, manufacture, and commercialize the drug globally. The drug, which is currently undergoing phase II clinical trials in China, is used to treat cardiovascular diseases.As part of the agreement, the Chinese medicine maker will receive milestone payments of up to $1.77 billion and royalties from sales outside the Greater China region, the filing said.Hengrui's shares jumped less than 4% in recent trade.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU1069347547.HKD","LU1917777945.USD","IE00BBT3K403.USD","LU2461242641.AUD","SG9999001176.USD","SG9999014542.SGD","SG9999002232.USD","LU0234572021.USD","LU0289739699.SGD","LU0320765489.SGD","LU2148510915.USD","BK4082","LU1974910355.USD","LU2023250843.SGD","LU2468319806.SGD","LU1066051811.HKD","LU0265550946.USD","IE00B4R5TH58.HKD","LU2112291526.USD","SG9999001440.SGD","SG9999015341.SGD","LU1934455194.USD","BK4550","LU0320765646.SGD","IE00B1BXHZ80.USD","IE0009355771.USD","CSII","LU2328871848.SGD","LU0058720904.USD","600276","IE00B2B36J28.USD","LU1064131003.USD","BK0196","LU1023059063.AUD","BK0188","BK4533","LU1061106388.HKD","LU1430594728.SGD","LU0006306889.USD","LU2361044865.SGD","IE00BLSP4452.SGD","LU0861579265.USD","BK0012","LU1929549753.HKD","MRK","BK0060","LU1969619763.USD","LU0965509010.AUD","IE00BJT1NW94.SGD","BK4588"],"gpt_icon":1},{"id":"2522022297","title":"Merck Enters Exclusive License Agreement for HRS-5346, an Investigational Oral Lipoprotein(a) Inhibitor, for Cardiovascular Disease from Jiangsu Hengrui Pharmaceuticals Co., Ltd.","url":"https://stock-news.laohu8.com/highlight/detail?id=2522022297","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522022297?lang=en_us&edition=fundamental","pubTime":"2025-03-25 18:45","pubTimestamp":1742899500,"startTime":"0","endTime":"0","summary":"RAHWAY, N.J., March 25, 2025----Merck , known as MSD outside of the United States and Canada, and Jiangsu Hengrui Pharmaceuticals Co., Ltd. , a global pharmaceutical company focused on scientific and technological innovation, today announced that the companies have entered into an exclusive license agreement for HRS-5346, an investigational oral small molecule Lipoprotein, or Lp, inhibitor currently being evaluated in a Phase 2 clinical trial in China.\"Elevated blood concentrations of Lp provides a well-documented risk factor for atherosclerotic cardiovascular disease, affecting as many as 1 in 5 adults globally,\" said Dr. Dean Y. Li, president, Merck Research Laboratories. \"HRS-5346, an investigational oral small molecule inhibitor of Lp formation, is an important addition that expands and complements our cardio-metabolic pipeline.\". About Hengrui PharmaJiangsu Hengrui Pharmaceuticals Co., Ltd.  is an innovative, global pharmaceutical company dedicated to the research, development and","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/merck-enters-exclusive-license-agreement-104500174.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["SG9999014559.SGD","LU0265550946.USD","LU1162221912.USD","BK4588","LU1929549753.HKD","LU2106854487.HKD","IE00B2B36J28.USD","LU2112291526.USD","IE00BFTCPJ56.SGD","BK4534","LU2361044865.SGD","BK4533","LU2089984988.USD","LU1941712348.USD","LU1037948897.HKD","LU1585245621.USD","LU0266013472.USD","SG9999013999.USD","LU1069347547.HKD","IE0009355771.USD","CSII","MRK","LU0238689110.USD","LU2023250504.SGD","LU1037948541.HKD","LU0861579265.USD","LU1983299246.USD","LU0203347892.USD","IE00B4R5TH58.HKD","LU1061106388.HKD","LU1066051498.USD","LU1093756168.USD","LU1291159041.SGD","SG9999001176.USD","SGXZ57979304.SGD","IE00BJJMRZ35.SGD","LU0289739699.SGD","LU1066053197.SGD","LU1917777945.USD","LU1989771016.USD","IE00BSNM7G36.USD","IE0002141913.USD","BK4007","BK4082","BK4559","LU0006306889.USD","LU0106261372.USD","SG9999014542.SGD","LU2361044949.HKD","LU1989772923.USD"],"gpt_icon":0},{"id":"2521744343","title":"BridgeBio to Present Cardiovascular Outcomes Data in Patients with Variant and Wild-type Transthyretin Amyloid Cardiomyopathy (ATTR-CM) from the ATTRibute-CM Study at the ACC Annual Scientific Sessions","url":"https://stock-news.laohu8.com/highlight/detail?id=2521744343","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521744343?lang=en_us&edition=fundamental","pubTime":"2025-03-24 19:30","pubTimestamp":1742815800,"startTime":"0","endTime":"0","summary":"PALO ALTO, Calif., March  24, 2025  (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, annou","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/03/24/3047739/0/en/BridgeBio-to-Present-Cardiovascular-Outcomes-Data-in-Patients-with-Variant-and-Wild-type-Transthyretin-Amyloid-Cardiomyopathy-ATTR-CM-from-the-ATTRibute-CM-Study-at-the-ACC-Annual-.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4207","CM","CSII","BK4082"],"gpt_icon":0},{"id":"2521960834","title":"Merck (NYSE:MRK) Unveils New Data On Cardiovascular Advances At ACC.25 Annual Conference","url":"https://stock-news.laohu8.com/highlight/detail?id=2521960834","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521960834?lang=en_us&edition=fundamental","pubTime":"2025-03-21 01:32","pubTimestamp":1742491922,"startTime":"0","endTime":"0","summary":"Merck (NYSE:MRK) experienced a 13% increase in its stock price over the last month, aided by several significant developments. The company's upcoming presentations at the American College of Cardiology's Annual Scientific Session, particularly the announcement of Phase 3 results for WINREVAIR™ targeting pulmonary arterial hypertension, highlight ongoing advancements in cardiovascular research. Additionally, positive Phase 3 trial results for the HIV-1 treatment DOR/ISL further underscore...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-mrk/merck/news/merck-nysemrk-unveils-new-data-on-cardiovascular-advances-at","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IE00BSNM7G36.USD","IE0009355771.USD","SG9999014559.SGD","LU1093756168.USD","LU1066051225.USD","SG9999013999.USD","LU1934455194.USD","LU1037948541.HKD","LU1571399168.USD","CSII","LU1941712264.USD","LU2361044949.HKD","SG9999015358.SGD","LU0985320562.USD","IE00BBT3K403.USD","SG9999015341.SGD","LU1585245621.USD","BK4516","LU0965509283.SGD","LU1061106388.HKD","LU1699723380.USD","LU1929549753.HKD","BK4588","BK4585","LU2324357040.USD","LU0289739699.SGD","LU2089984988.USD","LU0106261372.USD","LU1989771016.USD","LU0238689110.USD","IE00B2B36J28.USD","LU1066051498.USD","LU1066051811.HKD","LU0265550946.USD","LU1035773651.USD","BK4007","BK4082","NYSE","BK4533","LU1023059063.AUD","LU0320765646.SGD","LU0211331839.USD","SGXZ57979304.SGD","SG9999002224.SGD","LU0320765489.SGD","LU0058720904.USD","LU0861579265.USD","MRK","LU1430594728.SGD","LU1037948897.HKD"],"gpt_icon":0},{"id":"2520188780","title":"Press Release: AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event","url":"https://stock-news.laohu8.com/highlight/detail?id=2520188780","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520188780?lang=en_us&edition=fundamental","pubTime":"2025-03-19 20:01","pubTimestamp":1742385660,"startTime":"0","endTime":"0","summary":"AngioDynamics to Report Fiscal 2025 Third Quarter Financial Results on April 2, 2025 and Host Virtual Cardiovascular Investor Event. AngioDynamics, Inc. , a leading and transformative medical technology company focused on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options and improving patient quality of life, today announced that it will report financial results for the third quarter of fiscal year 2025 before the market open on Wednesday, April 2, 2025, followed by a virtual cardiovascular investor event, offering a deeper dive into the company's cardiovascular business and products.The Company's management will host a conference call at 8:00 am ET the same day to discuss the results.To participate in the conference call, dial 1-877-407-0784  or +1-201-689-8560 .A recording of the call will also be available, until Wednesday, April 09, 2025 at 11:59 PM ET. To hear this recording, dial 1-844-512-2921  or +1-412-317-6671  and enter the passco","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CSII","BK4181","BK4218","BK4585","HST","ANGO","BK4082","BK4588"],"gpt_icon":0},{"id":"2520932798","title":"Ansys and NVIDIA to Demonstrate New Era of In-Silico Cardiovascular Research at GTC","url":"https://stock-news.laohu8.com/highlight/detail?id=2520932798","media":"PR Newswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520932798?lang=en_us&edition=fundamental","pubTime":"2025-03-19 04:00","pubTimestamp":1742328000,"startTime":"0","endTime":"0","summary":"Ansys and NVIDIA unveil vision for the future of cardiovascular research by democratizing simulation. Ansys and NVIDIA's open-source technology narrows the gap between simulation and reality by enabling customized workflows, fostering collaboration, and making simulation more accessible to non-experts. A Python library, known as \"PyAnsys-Heart\" will enable partial and whole anatomical heart models in Ansys LS-Dyna nonlinear dynamics multiphysics simulation software. Using NVIDIA NIM microservices to build an AI-based speech-to-text code generator, Ansys empowers experts and non-experts to easily render photorealistic simulation results within OpenUSD-based applications with NVIDIA Omniverse. The demonstration at GTC showed how the framework can enable tailored treatments and outcome predictions for those with cardiovascular disease — the leading cause of death in the world. From within t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"yahoofinance","url":"https://finance.yahoo.com/news/ansys-nvidia-demonstrate-era-silico-200000364.html","rn_cache_url":null,"customStyle":"img, svg { display: none !important; }","selectors":"article","filters":"","directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/ansys-nvidia-demonstrate-era-silico-200000364.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["IE00B3M56506.USD","BK4548","LU1935042991.SGD","2NVD.UK","NVDS","SNVD.UK","CSII","LU0267386448.USD","IE00BQXX3C00.GBP","NVDA","IE00B19Z8W00.USD","LU2092937148.SGD","NVIW.SI","LU0979878070.USD","LU2244417387.USD","LU2417539215.USD","NVDD","LU1429558221.USD","LU2286300806.USD","LU1551013342.USD","NVD3.UK","NVD","NVDS.UK","ANSS","LU2458330243.SGD","LU2298064838.USD","LU0788109477.HKD","LU0889565833.HKD","NVDY","LU0353189680.USD","LU2097344431.USD","BK4533","IE00B1BXHZ80.USD","NVD2.UK","IE00BQXX3F31.USD","LU0965509010.AUD","NVDU","LU1316542783.SGD","LU2430703095.HKD","BK4587","LU1571399168.USD","LU0642271901.SGD","LU0868494617.USD","LU0348723411.USD","LU2491050154.USD","3NVD.UK","BK4605","BK4527"],"gpt_icon":1},{"id":"2514381094","title":"Press Release: Robotic Telesurgery Data from Collaboration with Corewell Health(TM) Accepted for Presentation at the Cardiovascular Research Technologies Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2514381094","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2514381094?lang=en_us&edition=fundamental","pubTime":"2025-02-25 21:30","pubTimestamp":1740490200,"startTime":"0","endTime":"0","summary":"Robotic Telesurgery Data from Collaboration with Corewell Health Accepted for Presentation at the Cardiovascular Research Technologies Annual Meeting. Research Collaboration demonstrates the feasibility of using the LIBERTY Endovascular Robotic System between separate and remote facilities in a coronary simulation model. BRAINTREE, Mass., Feb. 25, 2025  -- Microbot Medical Inc. , developer of the innovative LIBERTY Endovascular Robotic System, today announced its collaboration with Corewell Health has reached another meaningful milestone. Under a collaboration agreement, Microbot Medical and Corewell Health are working together to advance robotic telesurgery for endovascular applications. Led by Ryan Madder, M.D., Section Chief of Interventional Cardiology and Director of the Cardiac Cath Lab at Corewell Health in Grand Rapids, Michigan, the project assesses the feasibility of using LIBERTY to perform simulated cardiovascular interventional procedures across two sites within the Corewe","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["03160","BK4022","BK4213","TM","R","MBOT","BK4555","BK4585","BK4099","BK4604","CRT","BK4082","BK4588","BK4232","CSII"],"gpt_icon":0},{"id":"2512265881","title":"Globalspace Technologies Signs MoU for Maharashtra, India's Cardiovascular Disease Screening Project","url":"https://stock-news.laohu8.com/highlight/detail?id=2512265881","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512265881?lang=en_us&edition=fundamental","pubTime":"2025-02-19 14:25","pubTimestamp":1739946350,"startTime":"0","endTime":"0","summary":"Globalspace Technologies  signed a memorandum of understanding with Australia's MOD3RN Care for joint participation in the Indian state of Maharashtra's cardiovascular disease screening program using AI and digital technologies with GE Healthcare hardware, according to a BSE filing on Tuesday.MOD3RN Care will lead the project, while Globalspace Technologies will handle installation, deployment, and support.As part of the agreement, MOD3RN Care will receive 60% and GSTL 40% of profits during the initial rollout in Maharashtra.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["CSII","BK4082"],"gpt_icon":0},{"id":"2512165159","title":"Medtronic Q3 Earnings: Cardiovascular And Neuroscience Drive Growth, Surgical Revenue Dips, Reaffirms Annual Forecast","url":"https://stock-news.laohu8.com/highlight/detail?id=2512165159","media":"Benzinga","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512165159?lang=en_us&edition=fundamental","pubTime":"2025-02-18 22:30","pubTimestamp":1739889015,"startTime":"0","endTime":"0","summary":"Tuesday,Medtronic Plc  reported third-quarter 2025 sales of $8.29 billion, missing the consensus of $8.32 billion.The medical device maker reported adjusted EPS of $1.39, beating the consensus of $1.36. Revenue increased 2.5% year over year, as reported,and 4.1% organically.Also Read: Anteris Technologies Positioned To Capture 4%-5% Of US Transcatheter Valve Replacement Market By 2030: Analyst. “We delivered strong earnings this quarter, with significant improvements in both our gross margin and operating margin on the back of our ninth quarter in a row of mid-single digit organic revenue growth,” saidGeoff Martha, Medtronic chairman and chief executive officer.Cardiovascular segment revenue reached$3.04 billion, up 3.7% year over year as reported, andincreased 5% organically, with mid-single digit increases in Cardiac Rhythm & Heart Failure and Structural Heart & Aortic and a low-single-digit increase in Coronary & Peripheral Vascular, all on an organic basis.Neuroscience revenues of$","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/medtronic-q3-earnings-cardiovascular-neuroscience-143015853.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CSII","MDT"],"gpt_icon":0},{"id":"2512152834","title":"Published Data in The Lancet Diabetes & Endocrinology Highlights Unique Efficacy Benefits of Sotagliflozin to Reduce Major Adverse Cardiovascular Events (MACE)","url":"https://stock-news.laohu8.com/highlight/detail?id=2512152834","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512152834?lang=en_us&edition=fundamental","pubTime":"2025-02-18 21:00","pubTimestamp":1739883600,"startTime":"0","endTime":"0","summary":"Data reinforce unique clinical advantages of sotagliflozin Published study is aligned with research presentedin December 2024at the American Society of Hematology showing clinical benefits of sotaglif","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2025/02/18/3027794/0/en/Published-Data-in-The-Lancet-Diabetes-Endocrinology-Highlights-Unique-Efficacy-Benefits-of-Sotagliflozin-to-Reduce-Major-Adverse-Cardiovascular-Events-MACE.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4531","HCM","BK4588","BK4585","BK4007","BK4157","MACE","CSII","BK4082","BK4183"],"gpt_icon":0},{"id":"2512994159","title":"Medtronic 3Q Revenue Rises on Strength in Cardiovascular, Neuroscience","url":"https://stock-news.laohu8.com/highlight/detail?id=2512994159","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2512994159?lang=en_us&edition=fundamental","pubTime":"2025-02-18 20:09","pubTimestamp":1739880540,"startTime":"0","endTime":"0","summary":"Medtronic said steady demand for its cardiovascular and neuroscience products boosted revenue in its fiscal third quarter, though the top line was below analyst forecasts.The medical-technology company posted a profit of $1.29 billion, or $1.01 a share, for the quarter ended Jan. 24. That's down year over year from $1.32 billion, or 99 cents a share on a smaller base of outstanding shares.Stripping out one-time items, adjusted earnings were $1.39 a share. Analysts surveyed by FactSet had expected $1.36 a share.Revenue rose 2.5% from a year ago to $8.29 billion, behind analyst projections for $8.33 billion, according to FactSet.The top line rose more than 4% on an organic basis, with gains from its cardiovascular portfolio and neuroscience division that offset a pullback in its medical surgery business.Medtronic is sticking by its full-year guidance for revenue to rise 4.75% to 5% and earnings to be $5.44 to $5.50 a share.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["MDT","CSII"],"gpt_icon":0},{"id":"2511530671","title":"Pharma Foods, National Cerebral and Cardiovascular Center Launch Cadasil Drug Research Department","url":"https://stock-news.laohu8.com/highlight/detail?id=2511530671","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2511530671?lang=en_us&edition=fundamental","pubTime":"2025-02-13 08:18","pubTimestamp":1739405938,"startTime":"0","endTime":"0","summary":"Pharma Foods International  will establish Cadasil Drug Discovery Research Department in collaboration with the National Cerebral and Cardiovascular Center, according to a Wednesday filing on the Tokyo Stock Exchange.Cadasil, a genetic vascular disease with no established cure, is linked to NOTCH3 gene mutations, leading to migraines, strokes, and dementia.The National Cerebral and Cardiovascular Center, a research institute for cardiovascular diseases, is conducting Phase 2 clinical trials on adrenomedullin peptide as a potential treatment.Pharma Foods will apply its expertise in peptide research to develop new therapies for the disease, aligning with its broader mission of advancing healthcare innovations.Price : $940.00, Change: $-10, Percent Change: -1.05%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["NHLD","CSII","BK4082"],"gpt_icon":0},{"id":"2510680234","title":"Positive Outlook on Esperion’s Bempedoic Acid (BDA) for High-Risk Cardiovascular Patients Driven by Promising CLEAR Outcomes Trial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2510680234","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2510680234?lang=en_us&edition=fundamental","pubTime":"2025-02-11 19:26","pubTimestamp":1739273179,"startTime":"0","endTime":"0","summary":"Analyst Joseph Pantginis from H.C. Wainwright maintained a Buy rating on Esperion (ESPR – Research Report) and keeping the price target at $16.00. ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/positive-outlook-on-esperions-bempedoic-acid-bda-for-high-risk-cardiovascular-patients-driven-by-promising-clear-outcomes-trial-results?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/positive-outlook-on-esperions-bempedoic-acid-bda-for-high-risk-cardiovascular-patients-driven-by-promising-clear-outcomes-trial-results?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CSII","BK4082"],"gpt_icon":0},{"id":"2508518494","title":"Cardio Diagnostics Expands the Reach of its AI-Driven Precision Cardiovascular Medicine Tests by Partnering with Seven New Provider Organizations","url":"https://stock-news.laohu8.com/highlight/detail?id=2508518494","media":"Business Wire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2508518494?lang=en_us&edition=fundamental","pubTime":"2025-02-04 21:31","pubTimestamp":1738675860,"startTime":"0","endTime":"0","summary":"CHICAGO, February 04, 2025----Cardio Diagnostics Holdings, Inc. , an AI-driven Precision Cardiovascular Medicine company, today announced that the Company has partnered with seven new provider organizations. This expansion highlights the growing adoption of the Company’s cutting-edge blood tests, Epi+Gen CHD and PrecisionCHD, designed to transform the prevention, detection, and management of coronary heart disease.The new provider organizations span various regions and medical specialties including:. A forward-thinking concierge practice in Michigan, whose providers emphasize wellness and preventive health. Its services include weight management, hormone replacement therapy, hair loss treatment among many other personalized treatment plans using the latest medical technologies.A practice located in Illinois, offering a variety of primary care services including routine laboratory testing, vaccinations, and diabetes management, with a unique patient-centered approach to treating hyperte","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/cardio-diagnostics-expands-reach-ai-133100265.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CDIOW","BK4082","CSII","CDIO"],"gpt_icon":0},{"id":"2505099643","title":"Promising Potential of Esperion’s Non-Statin Drugs in Cardiovascular Disease Management","url":"https://stock-news.laohu8.com/highlight/detail?id=2505099643","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505099643?lang=en_us&edition=fundamental","pubTime":"2025-01-23 19:35","pubTimestamp":1737632129,"startTime":"0","endTime":"0","summary":"Esperion (ESPR – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Pantginis from H.C. ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/promising-potential-of-esperions-non-statin-drugs-in-cardiovascular-disease-management?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/promising-potential-of-esperions-non-statin-drugs-in-cardiovascular-disease-management?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["CSII","BK4082"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":2,"totalSize":37,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/CSII\",params:#limit:5,,,undefined,":[{"market":"US","date":"2023-04-28","symbol":"CSII","reason":null,"defaultRemindTime":1682688600000,"announcedDate":"2023-04-27","type":"delisting","dateTimestamp":1682654400000},{"date":"2023-02-09","symbol":"CSII","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":"2022/12","expectedEps":-0.15,"defaultRemindTime":1675933200000,"name":null,"time":"Pre-Market","dateTimestamp":1675918800000,"actualEps":null},{"market":"US","date":"2022-08-02","symbol":"CSII","fiscalQuarterEnding":"2022/06","expectedEps":-0.22,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1659412800000,"reportTimeType":"post","actualEps":-0.25},{"market":"US","date":"2022-05-04","symbol":"CSII","fiscalQuarterEnding":"2022/03","expectedEps":-0.28,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1651636800000,"reportTimeType":"pre","actualEps":-0.25},{"market":"US","date":"2021-11-09","symbol":"CSII","fiscalQuarterEnding":"2021/09","expectedEps":-0.1,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1636434000000,"reportTimeType":"pre","actualEps":-0.22}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"CSII\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"CSII\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0,"buy":0,"hold":0.6667,"sell":0.3333,"strongSell":0,"meanLabel":"HOLD","meanPercent":0.6667,"analysts":6,"updateTime":1676001600000},"@#url:\"https://hq.skytigris.cn/value_analysis/stock/CSII\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"CSII","date":"2023-04-26","current":-22.276361,"percent":0.602228,"low":-7142.134596,"twenty":-150.263532,"median":-47.492643,"eighty":648.895851,"high":1513.025574,"avg":-244.968737,"sd":1483.721277,"marketCap":843538979},"quantilePoints":[{"date":"2020-07-24","current":-110.335385,"twenty":-223.145513,"median":-18.68153,"eighty":649.10488,"marketCap":1169665412},{"date":"2020-07-31","current":-113.577255,"twenty":-223.145513,"median":-18.68153,"eighty":649.10488,"marketCap":1204032481},{"date":"2020-08-07","current":-45.121126,"twenty":-223.145513,"median":-18.68153,"eighty":649.10488,"marketCap":1228918979},{"date":"2020-08-14","current":-45.802801,"twenty":-223.145513,"median":-18.68153,"eighty":649.10488,"marketCap":1247485097},{"date":"2020-08-21","current":-47.110313,"twenty":-223.145513,"median":-18.68153,"eighty":649.10488,"marketCap":1283096489},{"date":"2020-08-28","current":-47.510849,"twenty":-223.145513,"median":-18.68153,"eighty":649.10488,"marketCap":1294005487},{"date":"2020-09-04","current":-47.481719,"twenty":-223.145513,"median":-18.68153,"eighty":649.10488,"marketCap":1293212105},{"date":"2020-09-11","current":-49.651896,"twenty":-223.145513,"median":-18.68153,"eighty":649.10488,"marketCap":1352319039},{"date":"2020-09-18","current":-52.200761,"twenty":-223.145513,"median":-18.68153,"eighty":649.10488,"marketCap":1421739934},{"date":"2020-09-25","current":-53.089223,"twenty":-223.145513,"median":-18.68153,"eighty":649.10488,"marketCap":1445938075},{"date":"2020-10-02","current":-55.251187,"twenty":-223.145513,"median":-18.735077,"eighty":649.10488,"marketCap":1504821337},{"date":"2020-10-09","current":-56.017337,"twenty":-223.145513,"median":-18.776934,"eighty":649.10488,"marketCap":1525688193},{"date":"2020-10-16","current":-56.842422,"twenty":-223.145513,"median":-18.865697,"eighty":649.10488,"marketCap":1548160192},{"date":"2020-10-23","current":-57.579104,"twenty":-223.145513,"median":-18.926233,"eighty":649.10488,"marketCap":1568224476},{"date":"2020-10-30","current":-52.525462,"twenty":-223.145513,"median":-18.979762,"eighty":649.10488,"marketCap":1430583484},{"date":"2020-11-06","current":-59.849141,"twenty":-223.145513,"median":-19.152472,"eighty":649.10488,"marketCap":1408369985},{"date":"2020-11-13","current":-61.878214,"twenty":-223.145513,"median":-19.216818,"eighty":649.10488,"marketCap":1456118141},{"date":"2020-11-20","current":-58.809028,"twenty":-223.145513,"median":-19.306102,"eighty":649.10488,"marketCap":1383894039},{"date":"2020-11-27","current":-60.343621,"twenty":-223.145513,"median":-19.411935,"eighty":649.10488,"marketCap":1420006090},{"date":"2020-12-04","current":-61.81001,"twenty":-223.145513,"median":-19.678226,"eighty":649.10488,"marketCap":1454513161},{"date":"2020-12-11","current":-62.321541,"twenty":-223.145513,"median":-19.76699,"eighty":649.10488,"marketCap":1466550511},{"date":"2020-12-18","current":-72.006531,"twenty":-223.145513,"median":-19.828442,"eighty":649.10488,"marketCap":1694457677},{"date":"2020-12-24","current":-75.178023,"twenty":-223.145513,"median":-19.951345,"eighty":649.10488,"marketCap":1769089249},{"date":"2020-12-31","current":-74.615339,"twenty":-223.145513,"median":-20.32132,"eighty":649.10488,"marketCap":1755848163},{"date":"2021-01-08","current":-79.06566,"twenty":-223.145513,"median":-20.427091,"eighty":649.10488,"marketCap":1860573111},{"date":"2021-01-15","current":-76.166984,"twenty":-223.145513,"median":-20.627956,"eighty":649.10488,"marketCap":1792361459},{"date":"2021-01-22","current":-79.543089,"twenty":-223.145513,"median":-20.814603,"eighty":649.10488,"marketCap":1871807971},{"date":"2021-01-29","current":-76.712617,"twenty":-223.145513,"median":-21.004841,"eighty":649.10488,"marketCap":1805201299},{"date":"2021-02-05","current":-82.625719,"twenty":-223.145513,"median":-21.125752,"eighty":649.10488,"marketCap":1667965385},{"date":"2021-02-12","current":-86.328944,"twenty":-223.145513,"median":-21.265484,"eighty":649.10488,"marketCap":1742722388},{"date":"2021-02-19","current":-82.685448,"twenty":-223.145513,"median":-21.492549,"eighty":649.10488,"marketCap":1669171143},{"date":"2021-02-26","current":-82.227523,"twenty":-223.145513,"median":-21.598052,"eighty":649.10488,"marketCap":1659926998},{"date":"2021-03-05","current":-80.117082,"twenty":-223.323098,"median":-21.772834,"eighty":649.309001,"marketCap":1617323544},{"date":"2021-03-12","current":-83.461931,"twenty":-223.323098,"median":-21.854907,"eighty":649.309001,"marketCap":1684845999},{"date":"2021-03-19","current":-80.435639,"twenty":-223.323098,"median":-21.959778,"eighty":649.309001,"marketCap":1623754254},{"date":"2021-03-26","current":-77.787635,"twenty":-223.145513,"median":-22.077677,"eighty":649.10488,"marketCap":1570298978},{"date":"2021-04-01","current":-74.442786,"twenty":-223.145513,"median":-22.365875,"eighty":649.10488,"marketCap":1502776524},{"date":"2021-04-09","current":-71.93415,"twenty":-223.323098,"median":-22.46194,"eighty":649.309001,"marketCap":1452134683},{"date":"2021-04-16","current":-77.608446,"twenty":-223.323098,"median":-22.539344,"eighty":649.309001,"marketCap":1566681704},{"date":"2021-04-23","current":-81.072753,"twenty":-223.323098,"median":-22.783943,"eighty":649.309001,"marketCap":1636615674},{"date":"2021-04-30","current":-80.276361,"twenty":-223.145513,"median":-22.907337,"eighty":649.10488,"marketCap":1620538899},{"date":"2021-05-07","current":-61.125515,"twenty":-223.145513,"median":-23.047069,"eighty":649.10488,"marketCap":1424346748},{"date":"2021-05-14","current":-62.685323,"twenty":-223.145513,"median":-23.118044,"eighty":649.10488,"marketCap":1460693394},{"date":"2021-05-21","current":-66.40818,"twenty":-223.145513,"median":-23.448954,"eighty":649.10488,"marketCap":1547443401},{"date":"2021-05-28","current":-67.545719,"twenty":-223.145513,"median":-23.542167,"eighty":649.10488,"marketCap":1573950347},{"date":"2021-06-04","current":-65.701526,"twenty":-223.145513,"median":-23.665911,"eighty":649.10488,"marketCap":1530976964},{"date":"2021-06-11","current":-68.131724,"twenty":-223.145513,"median":-23.842011,"eighty":649.10488,"marketCap":1587605441},{"date":"2021-06-18","current":-71.802875,"twenty":-223.145513,"median":-23.92517,"eighty":649.10488,"marketCap":1673150586},{"date":"2021-06-25","current":-75.887676,"twenty":-222.967928,"median":-24.312681,"eighty":648.900759,"marketCap":1768334621},{"date":"2021-07-02","current":-73.526419,"twenty":-222.967928,"median":-24.606789,"eighty":648.900759,"marketCap":1713312626},{"date":"2021-07-09","current":-74.112425,"twenty":-222.967928,"median":-44.751281,"eighty":648.900759,"marketCap":1726967720},{"date":"2021-07-16","current":-62.874913,"twenty":-222.967928,"median":-46.066945,"eighty":648.900759,"marketCap":1465111219},{"date":"2021-07-23","current":-67.631896,"twenty":-222.967928,"median":-46.851785,"eighty":648.900759,"marketCap":1575958449},{"date":"2021-07-30","current":-69.441618,"twenty":-222.967928,"median":-47.492643,"eighty":648.900759,"marketCap":1618128591},{"date":"2021-08-06","current":-116.556997,"twenty":-222.967928,"median":-48.109035,"eighty":648.900759,"marketCap":1564311458},{"date":"2021-08-13","current":-107.938662,"twenty":-222.967928,"median":-49.469834,"eighty":648.900759,"marketCap":1448644782},{"date":"2021-08-20","current":-109.829981,"twenty":-222.967928,"median":-51.159368,"eighty":648.900759,"marketCap":1474028176},{"date":"2021-08-27","current":-105.995219,"twenty":-222.967928,"median":-52.039983,"eighty":648.900759,"marketCap":1422561835},{"date":"2021-09-03","current":-108.212191,"twenty":-222.948196,"median":-53.089223,"eighty":648.898305,"marketCap":1452315813},{"date":"2021-09-10","current":-105.605751,"twenty":-222.948196,"median":-54.352435,"eighty":648.898305,"marketCap":1417334784},{"date":"2021-09-17","current":-109.620267,"twenty":-222.948196,"median":-55.22172,"eighty":648.898305,"marketCap":1471213610},{"date":"2021-09-24","current":-99.883567,"twenty":-222.948196,"median":-55.619529,"eighty":648.898305,"marketCap":1340537353},{"date":"2021-10-01","current":-102.201456,"twenty":-222.948196,"median":-56.577216,"eighty":648.898305,"marketCap":1371645743},{"date":"2021-10-08","current":-97.96826,"twenty":-222.928465,"median":-58.230986,"eighty":648.895851,"marketCap":1314832014},{"date":"2021-10-15","current":-101.354817,"twenty":-222.928465,"median":-59.228611,"eighty":648.895851,"marketCap":1360282997},{"date":"2021-10-22","current":-102.443353,"twenty":-222.928465,"median":-60.207213,"eighty":648.895851,"marketCap":1374892241},{"date":"2021-10-29","current":-106.071807,"twenty":-222.928465,"median":-61.050012,"eighty":648.895851,"marketCap":1423589723},{"date":"2021-11-05","current":-107.281292,"twenty":-222.928465,"median":-61.439537,"eighty":648.895851,"marketCap":1439822217},{"date":"2021-11-12","current":-55.251112,"twenty":-222.928465,"median":-61.46539,"eighty":648.895851,"marketCap":1102977952},{"date":"2021-11-19","current":-46.597813,"twenty":-222.928465,"median":-61.46539,"eighty":648.895851,"marketCap":930232140},{"date":"2021-11-26","current":-47.247826,"twenty":-222.928465,"median":-61.46539,"eighty":648.895851,"marketCap":943208351},{"date":"2021-12-03","current":-38.574214,"twenty":-222.928465,"median":-61.46539,"eighty":648.895851,"marketCap":770057033},{"date":"2021-12-10","current":-38.147643,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":761541394},{"date":"2021-12-17","current":-38.371085,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":766001967},{"date":"2021-12-23","current":-40.341437,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":805336107},{"date":"2021-12-31","current":-38.147643,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":761541394},{"date":"2022-01-07","current":-36.847617,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":735588972},{"date":"2022-01-14","current":-38.960159,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":777761658},{"date":"2022-01-21","current":-36.705426,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":732750426},{"date":"2022-01-28","current":-34.999142,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":698687871},{"date":"2022-02-04","current":-24.987669,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":721493944},{"date":"2022-02-11","current":-26.786556,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":773435015},{"date":"2022-02-18","current":-26.449265,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":763696064},{"date":"2022-02-25","current":-29.765963,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":859462415},{"date":"2022-03-04","current":-30.819998,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":889896636},{"date":"2022-03-11","current":-25.943327,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":749087638},{"date":"2022-03-18","current":-29.147595,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":841607671},{"date":"2022-03-25","current":-29.077326,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":839578723},{"date":"2022-04-01","current":-32.801585,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":947112973},{"date":"2022-04-08","current":-30.637299,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":884621371},{"date":"2022-04-14","current":-30.257846,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":873665051},{"date":"2022-04-22","current":-29.021111,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":837955565},{"date":"2022-04-29","current":-26.280619,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":758826589},{"date":"2022-05-06","current":-19.196392,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":624420233},{"date":"2022-05-13","current":-19.986315,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":650114860},{"date":"2022-05-20","current":-19.572546,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":636655770},{"date":"2022-05-27","current":-20.161854,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":655824777},{"date":"2022-06-03","current":-20.099161,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":653785521},{"date":"2022-06-10","current":-18.55693,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":603619820},{"date":"2022-06-17","current":-17.227853,"twenty":-222.889002,"median":-61.439537,"eighty":648.890944,"marketCap":560387590},{"date":"2022-06-24","current":-18.770084,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":610553291},{"date":"2022-07-01","current":-18.268545,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":594239242},{"date":"2022-07-08","current":-18.694853,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":608106183},{"date":"2022-07-15","current":-19.033392,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":619118167},{"date":"2022-07-22","current":-19.998854,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":650522711},{"date":"2022-07-29","current":-19.321776,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":628498745},{"date":"2022-08-05","current":-18.27617,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":674993785},{"date":"2022-08-12","current":-18.375557,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":678664446},{"date":"2022-08-19","current":-16.803903,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":620618538},{"date":"2022-08-26","current":-15.495084,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":572279932},{"date":"2022-09-02","current":-14.530107,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":536640452},{"date":"2022-09-09","current":-15.672551,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":578834319},{"date":"2022-09-16","current":-15.672551,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":578834319},{"date":"2022-09-23","current":-14.341549,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":529676415},{"date":"2022-09-30","current":-15.726213,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":580816217},{"date":"2022-10-07","current":-14.568872,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":538072166},{"date":"2022-10-14","current":-14.70503,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":543100878},{"date":"2022-10-21","current":-15.828331,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":584587751},{"date":"2022-10-28","current":-16.804128,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":620626852},{"date":"2022-11-04","current":-15.356608,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":598078472},{"date":"2022-11-11","current":-15.776012,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":614412548},{"date":"2022-11-18","current":-15.496409,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":603523164},{"date":"2022-11-25","current":-15.270577,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":594727893},{"date":"2022-12-02","current":-14.980221,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":583419686},{"date":"2022-12-09","current":-14.453279,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":562897386},{"date":"2022-12-16","current":-15.603949,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":607711389},{"date":"2022-12-23","current":-14.324231,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":557871516},{"date":"2022-12-30","current":-14.646849,"twenty":-222.908733,"median":-61.451938,"eighty":648.893398,"marketCap":570436190},{"date":"2023-01-06","current":-15.410378,"twenty":-221.981345,"median":-61.14502,"eighty":648.893398,"marketCap":600172585},{"date":"2023-01-13","current":-15.055498,"twenty":-220.996594,"median":-60.343621,"eighty":648.893398,"marketCap":586351444},{"date":"2023-01-20","current":-14.732881,"twenty":-218.210257,"median":-59.815039,"eighty":648.893398,"marketCap":573786770},{"date":"2023-01-27","current":-14.388755,"twenty":-216.298622,"median":-58.757875,"eighty":648.893398,"marketCap":560384451},{"date":"2023-02-03","current":-15.829781,"twenty":-213.098642,"median":-57.579104,"eighty":648.893398,"marketCap":616506661},{"date":"2023-02-10","current":-21.828798,"twenty":-209.864261,"median":-56.194141,"eighty":648.893398,"marketCap":826591078},{"date":"2023-02-17","current":-21.828798,"twenty":-206.639894,"median":-55.413615,"eighty":648.893398,"marketCap":826591078},{"date":"2023-02-24","current":-21.828798,"twenty":-204.396855,"median":-55.251112,"eighty":648.893398,"marketCap":826591078},{"date":"2023-03-03","current":-21.928523,"twenty":-200.181145,"median":-54.89758,"eighty":648.893398,"marketCap":830367383},{"date":"2023-03-10","current":-21.69583,"twenty":-195.294526,"median":-53.276878,"eighty":648.893398,"marketCap":821556006},{"date":"2023-03-17","current":-22.020055,"twenty":-191.11887,"median":-52.525462,"eighty":648.893398,"marketCap":833833428},{"date":"2023-03-24","current":-22.109205,"twenty":-188.575425,"median":-51.759312,"eighty":648.893398,"marketCap":837209272},{"date":"2023-03-31","current":-22.131493,"twenty":-184.820339,"median":-51.013718,"eighty":648.890944,"marketCap":838053233},{"date":"2023-04-06","current":-22.164924,"twenty":-177.300152,"median":-49.651896,"eighty":648.893398,"marketCap":839319174},{"date":"2023-04-14","current":-22.24293,"twenty":-171.241947,"median":-48.700677,"eighty":648.895851,"marketCap":842273038},{"date":"2023-04-21","current":-22.265218,"twenty":-159.435956,"median":-47.656498,"eighty":648.895851,"marketCap":843116999},{"date":"2023-04-26","current":-22.276361,"twenty":-150.263532,"median":-47.492643,"eighty":648.895851,"marketCap":843538979}],"updateTime":1753181782233}}}